Nicotinamide supplement study for glaucoma patients
Treatments studied
Part of Eyes & vision clinical trials.
This trial tests whether a vitamin B3 supplement called nicotinamide can help slow down vision loss in people with glaucoma. It is for those with moderate disease who are already on treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 21 years or older.
- You have a type of glaucoma (like open-angle, angle-closure, normal-tension, pigmentary, or pseudoexfoliative glaucoma) in at least one eye.
- Your vision is at least 6/18 (with glasses or contact lenses) and you have a detectable visual field defect from glaucoma.
- You have had at least two visual field tests before that meet quality standards.
- You are not currently taking allopurinol, carbamazepine, or primidone, and you do not have active liver disease or end-stage kidney failure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether nicotinamide (a form of vitamin B3/niacin) can slow or affect glaucoma progression. You may be eligible if you have newly diagnosed, untreated glaucoma or if you have treated glaucoma with measurable visual field changes.
This study measures levels of nicotinamide (a form of vitamin B3) in different eye fluids of people with glaucoma and compares them to people without glaucoma. It aims to understand how nicotinamide relates to cell damage and aging in the eye, which could help develop new treatments.
This trial tests whether NAD precursor supplements can improve nerve health and vision in people with glaucoma. If you have glaucoma with mild to moderate vision loss, this study may help understand if these supplements could protect your optic nerve.
This trial tests whether a dietary supplement (DHA + citicoline) can help protect vision in people with glaucoma. You may qualify if you have confirmed glaucoma in at least one eye and are between 50 and 75 years old.
This study tests whether metformin can slow damage to the optic nerve in people with glaucoma. It uses eye scans and vision tests to look for changes over time, aiming to help preserve sight.
This trial tests whether nicotinamide (a form of vitamin B3) can slow vision changes from open-angle glaucoma. It compares nicotinamide versus a placebo (inactive pill) in adults with early to moderate disease.
Hear when a new Glaucoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.